Location History:
- Saint Andeol le Chateau, FR (2011 - 2018)
- Saint Andéol le Château, FR (2018 - 2020)
Company Filing History:
Years Active: 2011-2020
Title: **Isabelle Legastelois: Innovator in Recombinant Protein Multimerization**
Introduction
Isabelle Legastelois, based in Saint Andeol le Chateau, France, is a prominent inventor known for her significant contributions to the field of recombinant proteins. With a remarkable portfolio of five patents, her work primarily focuses on the multimerization of recombinant proteins, potentially transforming pharmaceutical compositions.
Latest Patents
Among Isabelle's latest patents is the innovative development surrounding the "Multimerization of Recombinant Protein by Fusion to a Sequence from Lamprey." This invention encompasses polymerized recombinant proteins and the corresponding recombinant nucleic acids that code for them. Furthermore, it includes expression cassettes and transformed host cells, alongside methods for multimerizing recombinant proteins. The implications of her work are vast, as these polymerized proteins can be applied in pharmaceutical or immunogenic compositions, particularly as antigens, antibodies, or scaffolds. Notably, the polymerized recombinant protein developed could serve as an influenza haemagglutinin.
Career Highlights
Isabelle has made a significant impact in the biopharmaceutical sector through her work with notable companies such as Sanofi Pasteur Inc. and Sanofi Pasteur SA. Her involvement in these organizations has equipped her with valuable industry experience, fostering her endeavors in inventive research and development.
Collaborations
Throughout her career, Isabelle has collaborated with skilled professionals, including Catherine Moste and Régis Sodoyer. These partnerships have played a crucial role in advancing her research and the successful launch of her patented inventions.
Conclusion
Isabelle Legastelois stands out as an innovator in the field of recombinant proteins, with her groundbreaking patents contributing significantly to the understanding and application of these proteins in healthcare. Her dedication to advancing biopharmaceuticals reflects her commitment to innovation and excellence in the scientific community.